Journal article
Toxicity, tolerability & compliance of concurrent capecitabine or 5-fluorouracil in the radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort
- Abstract:
-
Purpose Chemoradiotherapy (CRT) with mitomycin C (MMC) and 5-fluouracil (5-FU) is established as the standard of care for the radical management of patients with anal squamous cell carcinoma (ASCC). There is emerging use of the oral fluoropyrimidine-derivative capecitabine as an alternative to 5-FU despite limited evidence for its tolerability and toxicity. Methods & Materials A national cohort evaluation of anal cancer management within the United Kingd... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 1.3MB)
-
- Publisher copy:
- 10.1016/j.ijrobp.2018.04.033
Authors
Funding
+ Medical Research Council
More from this funder
Funding agency for:
Hawkins, M
Grant:
MC_UU_00001/2
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- International Journal of Radiation Oncology*Biology*Physics Journal website
- Volume:
- 101
- Issue:
- 5
- Pages:
- 1202-1211
- Publication date:
- 2018-04-19
- Acceptance date:
- 2018-04-10
- DOI:
- ISSN:
-
0360-3016
- Source identifiers:
-
836654
Item Description
- Keywords:
- Pubs id:
-
pubs:836654
- UUID:
-
uuid:5eb342de-9192-4b63-975f-6743b463cef0
- Local pid:
- pubs:836654
- Deposit date:
- 2018-04-17
Terms of use
- Copyright holder:
- Crown Copyright
- Copyright date:
- 2018
- Notes:
- Crown Copyright © 2018 Published by Elsevier Inc. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.ijrobp.2018.04.033
If you are the owner of this record, you can report an update to it here: Report update to this record